Product Development - The company is focused on developing therapeutics for mast cell driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma [121]. - The lead product candidate, briquilimab, demonstrated a rapid onset of clinical efficacy with complete responses observed as early as week 2 post-dose [125]. - In the Phase 1b/2a BEACON study for CSU, briquilimab showed UAS7 reductions of up to 29 points at the 120mg Q12W dose level [125]. - In the Open Label Extension study, 73% of participants achieved a complete response at the week 12 assessment with briquilimab at 180mg Q8W [129]. - The Phase 1b/2a SPOTLIGHT study for CIndU reported that 93% of participants in the 40mg and 120mg cohorts achieved a clinical response [136]. - The company halted enrollment in the ETESIAN study due to concerns over drug product lot efficacy, with results expected in the second half of 2025 [132]. - The ongoing investigation into the BEACON study's efficacy results is expected to conclude in Q4 2025 [127]. - The company discontinued the SCID program to focus resources on mast cell disease development programs [133]. - The company aims to broaden its pipeline with additional mast cell indications and next-generation products [134]. Financial Performance - For the three months ended September 30, 2025, the company reported a net loss of $18.7 million, compared to a net loss of $18.6 million for the same period in 2024, reflecting a slight increase in losses [139][153]. - The accumulated deficit as of September 30, 2025, was $307.6 million, indicating ongoing financial challenges [140]. - The company incurred a net loss of $66.7 million for the nine months ended September 30, 2025 [192]. - The company generated negative operating cash flows of $55.3 million for the nine months ended September 30, 2025, compared to $41.5 million for the same period in 2024 [139]. - Research and development expenses for the three months ended September 30, 2025, were $14.4 million, a decrease of $0.1 million from $14.5 million in the same period in 2024 [153][155]. - Research and development expenses increased by $15.7 million from $36.1 million for the nine months ended September 30, 2024 to $51.7 million for the same period in 2025 [167]. - Total program costs for the three months ended September 30, 2025 were $9.3 million, an increase of 6.4% from $8.8 million for the same period in 2024 [161]. - Total program costs for the nine months ended September 30, 2025 were $34.9 million, an increase of 65% from $21.1 million for the same period in 2024 [172]. - General and administrative expenses decreased by $0.6 million from $5.4 million for the three months ended September 30, 2024 to $4.8 million for the same period in 2025 [162]. - General and administrative expenses increased by $1.4 million from $14.9 million for the nine months ended September 30, 2024 to $16.3 million for the same period in 2025 [173]. - Total other income, net decreased by $0.9 million from $1.3 million for the three months ended September 30, 2024 to $0.4 million for the same period in 2025 [163]. - Total other income, net decreased by $2.7 million from $4.0 million for the nine months ended September 30, 2024 to $1.3 million for the same period in 2025 [174]. Funding and Capital Management - The company entered into an underwriting agreement on September 18, 2025, and closed a public offering on September 22, 2025, raising net proceeds of $27.5 million from the issuance of 11,670,707 shares of common stock [138]. - The company plans to monitor expenses and raise additional capital through public and private equity, debt financings, and strategic alliances [141]. - The company anticipates needing substantial additional funding to support ongoing operations and product development [182]. - As of September 30, 2025, $93.5 million remains available under the ATM Prospectus and $170.0 million under the Shelf Registration Statement [181]. - The company filed a new universal shelf registration statement allowing the sale of up to $263.5 million in various securities as of September 30, 2025 [178]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $34.6 million, down from $47.5 million in the same period in 2024 [195][196]. Corporate Actions - The company implemented a corporate reorganization on July 8, 2025, resulting in a workforce reduction of approximately 50%, equating to 20 employees, and incurred a total cost of approximately $1.8 million related to severance payments [137][139]. - The company has leased approximately 25,900 square feet of office space in Redwood City, California, with rent commitments of $1.8 million due within the next 12 months [187]. - The company has contractual obligations related to license agreements with Stanford, including milestone payments of up to $9.0 million [188][189]. Risks and Challenges - The company is subject to risks associated with the development of new drug candidates, which may lead to unforeseen expenses and delays [182]. - The company does not currently have a sales and marketing infrastructure to support the commercial launch of its product candidates, which may require significant investment prior to product approval [144]. - The company expects its expenses to increase substantially as it advances product candidates through clinical trials and establishes a sales and marketing infrastructure [142].

Financial Performance - Jasper Therapeutics reported a net loss of $18.7 million for the third quarter of fiscal 2025, translating to a net loss per share of $1.13[7] - Total operating expenses for the third quarter were $19.2 million, compared to $19.9 million in the same quarter of the previous year[11] - The accumulated deficit increased to $307.6 million as of September 30, 2025, compared to $240.9 million at the end of 2024[13] Expenses - Research and development expenses for the quarter were $14.4 million, while general and administrative expenses totaled $4.8 million[7] - The total liabilities as of September 30, 2025, were $45.9 million, with current liabilities at $21.0 million[13] Cash Position - As of September 30, 2025, cash and cash equivalents amounted to $50.9 million, following a successful $30 million underwritten offering of common stock and warrants[7] Clinical Studies - The company is investigating anomalous efficacy results from the BEACON study and plans to report final conclusions in the fourth quarter of 2025[4] - Initial data from the ETESIAN study in allergic asthma is expected to be reported in the fourth quarter of 2025, with additional data from the BEACON study anticipated in the first half of Q1 2026[2] - Jasper continues to enroll additional patients in the BEACON study and expects to complete dose selection for the planned Phase 2b CSU study by mid-2026[7] Product Potential - The company believes briquilimab has the potential to be a highly differentiated therapy for mast cell diseases based on preliminary results[2]

Core Insights - Jasper Therapeutics is focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][6] - The company reported a net loss of $18.7 million for the fiscal quarter ended September 30, 2025, with a basic and diluted net loss per share of $1.13 [5][9] - Jasper has successfully completed a $30 million underwritten offering of common stock and warrants, extending its cash runway through the first half of 2026 [5] Financial Results - For the three months ended September 30, 2025, research and development expenses were $14.4 million, while general and administrative expenses were $4.8 million [5][9] - Cash and cash equivalents as of September 30, 2025, totaled $50.9 million, down from $71.6 million as of December 31, 2024 [10] - Total operating expenses for the third quarter of 2025 were $19.2 million, compared to $19.9 million for the same period in 2024 [9] Clinical Development - The ongoing investigation into anomalous efficacy results from the BEACON study is nearing completion, with no evidence of drug substance or drug product issues identified [2][5] - Initial data from the ETESIAN study in allergic asthma is expected to be reported in the fourth quarter of 2025, along with updated data from CSU and CIndU patients in the open-label extension study [2][5] - The company plans to commence the Phase 2b CSU study in mid-2026, pending the completion of dose selection based on additional data from ongoing studies [5][6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, potentially leading to disruptive cost-reduction measures and overstated business and financial prospects [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which negatively impacted its regulatory and commercial prospects [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Jasper to contact them, highlighting a deadline of November 18, 2025, for seeking the role of lead plaintiff in a federal securities class action against the company [4][8]. Allegations Against Jasper - The complaint alleges that Jasper and its executives made false and misleading statements, failing to disclose critical issues regarding their manufacturing processes and the implications for their product, briquilimab [6]. - Specific allegations include: - Lack of necessary controls for third-party manufacturers to comply with cGMP regulations [6]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects [6]. - Overstated business and financial prospects due to these failures [6]. Stock Price Impact - Following a press release on July 7, 2025, which revealed significant issues with a drug product lot and the halting of several studies, Jasper's stock price plummeted by $3.73 per share, or 55.1%, closing at $3.04 per share [7].

Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3][6]. - The lawsuit claims that Jasper Therapeutics made false statements regarding its manufacturing controls and the suitability of its products for clinical trials, which misled investors about the company's financial and business prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own history of successful settlements and recognition in the field [4]. - The firm has achieved significant recoveries for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Rosen Law Firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact its products and financial prospects [5] - Specific claims include the lack of necessary controls for third-party manufacturers, increased risk of confounding study results, and overstated business and financial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages due to these misleading public statements [5]

Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to contact them regarding a class action lawsuit due to allegations of misleading business operations [1][2]. Summary by Sections Allegations - The lawsuit claims that Jasper Therapeutics made false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of products like briquilimab [3]. - Potential for disruptive cost-reduction measures due to the aforementioned failures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Public statements made by defendants were materially false and misleading [3]. Class Action Participation - Investors may be eligible to participate in the class action against Jasper Therapeutics, with a deadline to file motions for lead plaintiff by November 18, 2025 [4]. - Investors do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and lack of proper manufacturing controls [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the regulatory prospects of its products, particularly briquilimab [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [4]. Group 3: Case Background - The lawsuit alleges that Jasper Therapeutics failed to ensure that third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could negatively impact the clinical and commercial prospects of its products [5]. - The failure to disclose these issues allegedly led to inflated public statements regarding the company's business and financial outlook [5].